The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study. The New Drug Application (NDA) for SPN-830 ...
Credit: Thinkstock. SPN-830 provides a continuous subutaneous infusion of apomorphine through an infusion pump The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to ...
If a patient with Parkinson’s disease fits into the “5-2-1” screening criteria– five times of oral tablet, stiffness for two hours and one hour of uncontrollable movements despite medication– laid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback